about
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximabOvercoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancerIrreversible EGFR-TKIs: dreaming perfectionMET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.First-line crizotinib versus chemotherapy in ALK-positive lung cancer.Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.Cancer Stem Cells Sensitivity Assay (STELLA) in Patients with Advanced Lung and Colorectal Cancer: A Feasibility StudyGemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study.Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancer.Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer.A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy.Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids.Gemcitabine in non-small cell lung cancer.Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.HER2 in solid tumors: more than 10 years under the microscope; where are we now?Emerging drugs for non-small cell lung cancer.Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens.PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patientsInsulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients.Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trialsEGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center.Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma.p95HER2 truncated form in resected non-small cell lung cancerIncreased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancermicroRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers.Clinical experience with gefitinib: an update.Role of gemcitabine in cancer therapy.Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance.ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases.Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC).Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patientsLung cancer screening with spiral CT: baseline results of the randomized DANTE trial.
P50
Q24600031-2223CCA0-E548-4B23-A7F8-BD8324A7AA4FQ26745427-63A61D80-2064-4586-B01D-73C69DFCAF91Q26866186-69093872-CB91-4BAF-BDC3-EE01C161F614Q27851406-5272F4B3-BF4D-4CCD-9680-FD2612AEAFACQ27851573-CD5C4D33-2E84-4BA6-B180-FBF30FC2874EQ27851615-8F47E847-2EF3-4872-8648-C87A4C125D14Q27853101-7ACCC60D-66EB-4033-9C09-8934CD3FA7F1Q27853124-8D195A63-54D6-4FEE-9161-76AAE58EAF2EQ27853282-1E16D516-7EE2-4CA2-9CDA-A1D7471DD6F8Q28547124-16E05839-937D-41FF-860D-2B694D41C3A5Q33348744-022F7746-7F8A-41FC-B691-8504D0DE0CACQ33357843-EC23D3B4-4BDF-47FD-8406-52586D46554CQ33366782-DDAA3687-9997-4995-8AD6-39D30500CE18Q33370925-F23CBB0E-9069-4F0F-98BA-B71D2915AD37Q33378691-9CC8D3F1-6696-4307-8393-40C195A60CF0Q33379936-376236F4-8BBF-45F8-BF7C-A02E09934B0EQ33385120-893B8BDD-D00B-4972-A5D2-A26BF59B6E4CQ34045543-7E8E8BC0-1897-47AC-BEFC-BC6DFC5D4996Q34130737-2BE4A87D-B356-4F85-A505-CF40F3378DB1Q34535487-0D5670BE-B9BF-4EEF-BD59-22AE22A60EE4Q34557318-3A252722-1D23-4D47-9D3C-44D696482246Q34662482-59E8AAF6-855A-41B6-A870-748CEC099C22Q35211263-F818C131-6CE9-4937-A9F6-3B1977A64A7DQ35581167-ED507CBF-19DA-4579-8B91-BDF5AE73513AQ35583723-2645A281-55A8-4370-BC99-768A6B5FF6D2Q35677709-726F270A-621D-4246-93EF-3DA687D763A9Q35994860-4CC8EA95-8AF5-43D0-9B46-998B58F68773Q35996048-1CC0DD85-F12A-4AAF-BBE1-886681E00783Q36066994-27A86EA7-DF71-4BE6-9F00-38D4560F2AA3Q36123353-89A6A310-F80C-42EE-B265-E9AB6FF75D71Q36170889-A7E34160-581D-4A76-BF4A-9652638EBFC9Q36184256-2D19DAD6-7433-4320-9292-AB0262081DBCQ36354817-0FD92E4E-D3DB-48C6-A588-02C5528315FEQ36418927-5799B0A2-2257-4794-BE8F-9CC3EB4840B2Q36429373-92A6C8AB-C3A3-4E43-97E8-5E6266396F9FQ36445820-CFBA45C2-FDFF-47A1-ACBE-2D91A5F273B6Q36670880-E6A90BA8-884A-42A6-85A7-0E76B518D8DCQ36673684-16EEB7DC-5555-486A-A0B3-121614BA6BB0Q36755257-4183FD09-0E82-43D6-B1E1-592D6547464AQ36971113-13780102-5AFA-452E-8E6E-3BDB55332AB2
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Federico Cappuzzo
@ast
Federico Cappuzzo
@en
Federico Cappuzzo
@es
Federico Cappuzzo
@nl
Federico Cappuzzo
@sl
type
label
Federico Cappuzzo
@ast
Federico Cappuzzo
@en
Federico Cappuzzo
@es
Federico Cappuzzo
@nl
Federico Cappuzzo
@sl
prefLabel
Federico Cappuzzo
@ast
Federico Cappuzzo
@en
Federico Cappuzzo
@es
Federico Cappuzzo
@nl
Federico Cappuzzo
@sl
P1053
R-2827-2016
P106
P1153
6701585563
P21
P31
P3829
P496
0000-0002-6295-6767